Heat Shock Proteins and Ovarian Cancer: Important Roles and Therapeutic Opportunities

Ovarian cancer is a serious cause of death in gynecological oncology. Delayed diagnosis and poor survival rates associated with late stages of the disease are major obstacles against treatment efforts. Heat shock proteins (HSPs) are stress responsive molecules known to be crucial in many cancer type...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2019-09, Vol.11 (9), p.1389
Main Authors: Hoter, Abdullah, Naim, Hassan Y.
Format: Article
Language:English
Subjects:
Angiogenesis
Antitumor agents
Apoptosis
Cancer therapies
Chemotherapy
Clusterin
Cytochrome
Diagnosis
Drug resistance
Heat shock proteins
Hormones
Kinases
Medical prognosis
Medical research
Metastases
Metastasis
Molecular weight
Ovarian cancer
Physiology
Prostate
Review
Therapeutic targets
Tumors
Vascular endothelial growth factor
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ovarian cancer is a serious cause of death in gynecological oncology. Delayed diagnosis and poor survival rates associated with late stages of the disease are major obstacles against treatment efforts. Heat shock proteins (HSPs) are stress responsive molecules known to be crucial in many cancer types including ovarian cancer. Clusterin (CLU), a unique chaperone protein with analogous oncogenic criteria to HSPs, has also been proven to confer resistance to anti-cancer drugs. Indeed, these chaperone molecules have been implicated in diagnosis, prognosis, metastasis and aggressiveness of various cancers. However, relative to other cancers, there is limited body of knowledge about the molecular roles of these chaperones in ovarian cancer. In the current review, we shed light on the diverse roles of HSPs as well as related chaperone proteins like CLU in the pathogenesis of ovarian cancer and elucidate their potential as effective drug targets.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers11091389